
# The role of epidemiology in knowledge integration and meta-research

#### John P.A. Ioannidis

C.F. Rehnborg Professor in Disease Prevention
Professor of Medicine and Professor of Health Research and Policy
Director, Stanford Prevention Research Center
Stanford University School of Medicine
Professor of Statistics (by courtesy)
Stanford University School of Humanities and Sciences



Adapted from *Cancer Epidemiol Biomarkers Prev.* 2013; 22(1):3-10, Knowledge Integration in Cancer: Current Landscape and Future Prospects, with permission from AACR.

Table 1. Published articles in cancer literature

|                          | PubMed    | Treatment | Prevention | Not (trial or treatment) |
|--------------------------|-----------|-----------|------------|--------------------------|
| Cancer                   | 2,673,926 | 1,360,697 | 208,187    | 1,295,958                |
| +Animal                  | 481,080   | 206,009   | 40,891     | 269,653                  |
| +Cell                    | 1,118,600 | 510,286   | 66,935     | 604,187                  |
| +Cohort                  | 53,567    | 29,808    | 8,683      | 22,819                   |
| +Case-control            | 59,248    | 11,255    | 5,848      | 26,973                   |
| +Risk                    | 267,490   | 158,529   | 58,002     | 105,276                  |
| +Biomarker               | 204,419   | 91,298    | 15,675     | 111,025                  |
| +Clinical trial, type    | 105,939   | 93,172    | 14,807     | 4,535                    |
| +RCT, type               | 34,449    | 31,862    | 8,047      | 0                        |
| +Meta-analysis, type     | 6,406     | 3,902     | 1,153      | 2,332                    |
| +Systematic review, type | 28,922    | 21,398    | 5,755      | 6,763                    |
| +Review, type            | 314,176   | 201,162   | 39,859     | 111,234                  |

NOTE: Search strategies: treatment: "treatment", prevention: "prevention OR screening [ti] OR screening [tw]", Not trial or treatment: "NOT (trial\* OR treatment)."

Abbreviation: RCT, randomized controlled trial.

Cancer Epidemiol Biomarkers Prev; 2012

Cancer Epidemiology, Biomarkers & Prevention

#### Table 2. Different approaches to KM and KS

#### Knowledge management

Published data: optimization of search engines, curation and cleaning, harmonization

Unpublished data: detection, registration, cleaning
Deposition of raw datasets in public: documentation,
access control, ease of use, credit, independence
Live stream information

#### Knowledge synthesis

Same-level of information

Systematic reviews of published information

Meta-analyses of published information

Meta-analyses including also retrieved unpublished data

Field synopses of many meta-analyses

Collaborative meta-analyses of previously collected individual-level data

Collaborative meta-analyses of prospectively collected data from existing studies

Prospective consortia and meta-analyses thereof

#### Multiple levels of information

Cross-design synthesis and multilevel evidence appraisals

Modeling with real or simulated data Meta-research (research on research) Reprinted from *Cancer Epidemiol Biomarkers Prev.* 2013; 22(1):3-10,
Knowledge Integration in
Cancer: Current
Landscape and Future
Prospects, with permission
from AACR.

Table 3. Systematic reviews and meta-analyses in different fields of cancer (excluding trials and treatment)

| Search terms                        | All articles, N (all) | n (SR) | n (MA) | n (SR)/n (MA) | n (all)/n (MA) |
|-------------------------------------|-----------------------|--------|--------|---------------|----------------|
| Gene/genome/genetic                 | 268,597               | 1,999  | 920    | 2.2           | 291            |
| Epigenetic/methylation/mutation     | 115,763               | 497    | 159    | 3.1           | 728            |
| Immune/allergy/asthma               | 29,046                | 107    | 25     | 4.3           | 1162           |
| Hormone                             | 53,679                | 148    | 51     | 2.9           | 1,032          |
| Social/socioeconomic                | 11,531                | 224    | 50     | 4.5           | 231            |
| Diet/dietary/nutrition/nutritional  | 19,549                | 289    | 147    | 2.0           | 133            |
| Physical activity/exercise/obesity  | 8,919                 | 192    | 74     | 2.6           | 121            |
| Virus/bacteria/infection/infectious | 88,881                | 331    | 109    | 3.0           | 815            |
| Carcinogen                          | 30,286                | 201    | 88     | 2.3           | 344            |
| Radiation                           | 30,124                | 229    | 86     | 2.6           | 350            |
| Occupation/occupational             | 16,839                | 344    | 177    | 1.9           | 95             |
| Smoking/smoke/tobacco               | 20,660                | 413    | 232    | 1.8           | 89             |
| Alcohol                             | 17,921                | 170    | 83     | 2.0           | 215            |
| Biomarker                           | 72,709                | 373    | 97     | 3.8           | 750            |

Reprinted from *Cancer Epidemiol Biomarkers Prev*. 2013; 22(1):3-10, Knowledge Integration in Cancer: Current Landscape and Future Prospects, with permission from AACR.

# Examples of knowledge integration at the meta-research level


- Associations
- Predictions
- Treatments

#### Nutrients and cancer risk


- Open a popular cookbook
- Randomly check 50 ingredients
- How many of those are associated with significantly increased or significantly decreased cancer risk in the scientific literature?

#### Associated with cancer risk

veal, salt, pepper spice, flour, egg, bread, pork, butter, tomato, lemon, duck, onion, celery, carrot, parsley, mace, sherry, olive, mushroom, tripe, milk, cheese, coffee, bacon, sugar, lobster, potato, beef, lamb, mustard, nuts, wine, peas, corn, cinnamon, cayenne, orange, tea, rum, raisin




Reprinted from Schoenfeld JD and Ioannidis JPA. Is everything we eat associated with cancer? A systematic cookbook review. *Am J Clin Nutr*. 2013; 97(1):127-134, American Society for Nutrition.



Reprinted from Schoenfeld JD and Ioannidis JPA. Is everything we eat associated with cancer? A systematic cookbook review. *Am J Clin Nutr.* 2013; 97(1):127-134, American Society for Nutrition.


### Prognostic tumor markers




# Further analysis of claims in "negative" prognostic studies

|  | Database<br>1<br>N (%) | Database<br>2<br>N (%) |
|--|------------------------|------------------------|
| Not admitted to be fully "negative"                                    | 27 (7.9)               | 45 (2.8)               |
| Significance for other (non-prognostic) analyses                       | 6 (1.7)                | 11 (0.6)               |
| Discussion of non-significant trends                                   | 2 (0.6)                | 5 (0.3)                |
| Offered apologies  | 9 (2.8)                | 13 (0.8)               |
| Significance for other analyses + Discussion of non-significant trends | 1 (0.3)                | 3 (0.2)                |
| Significance for other analyses + Offered apologies                    | 6 (1.7)                | 7 (0.5)                |
| Discussion of non-significant trends + Offered apologies               | 3 (0.8)                | 4 (0.3)                |
| All three mechanisms   | -                      | 2 (0.1)                |
| Admitted to be fully "negative"  | 5 (1.5)                | 21 (1.3)               |
|  |                        |                        |

# Effect sizes for the top-cited biomarkers in the biomedical literature






Nair VS, Maeda LS, and Ioannidis JPA. Clinical outcome prediction by microRNAs in Human Cancer: A systematic review. *J Natl Cancer Inst*. 2012; 104(7): 528-540. Used by permission of Oxford University Press.

## Field synopses

Chatzinasiou F, Lill CM, Kypreou K, et al. Comprehensive Field Synopsis and Systematic Meta-analyses of Genetic Association Studies in Cutaneous Melanoma. *J Natl Cancer Inst*. 2011; 103(16): 1227-1235.

#### **Published Genetic Meta-Analyses by Country, Year**




Ioannidis JPA, Chang C, Lam TK, Schully SD, and Khoury MJ. Submitted to Cancer Epidemiol Biomarkers Prev, 2013.

# Replicated: only 6 of 53 landmark studies for Amgen oncology drug target projects


• "The failure to win "the war on cancer" has been blamed on many factors, ... But recently a new culprit has emerged: too many basic scientific discoveries... are wrong."

Source: Begley S. Reuters. March 25, 2012.

# 700 randomized trials on advanced breast cancer: it all works (more or less)




# 1200 (and counting) clinical trials of bevacizumab



Meta-analysis forest plot for survival with bevacizumab  $\nu$  control in trials of patients with cancer. Each trial is shown by its year of publication, name of first author, and type of malignancy as well as the hazard ratio for survival and 95% confidence interval. Also shown are summary estimates including all trials and excluding the three trials stopped early, which showed large treatment benefits (Hurwitz 2004, Sandler 2006, Escudier 2007)

Reproduced from Ioannidis JPA and Karassa FB. The need to consider the wider agenda in systematic reviews and metaanalyses: breadth, timing, and depth of the evidence. 340:c4875, with permission from BMJ Publishing Group, Ltd. Pereira TV, Horwitz RI, and Ioannidis JPA. Empirical Evaluation of Very Large Treatment Effects of Medical Interventions. *JAMA*. 2012; 308(16):1676-1684.




Pereira TV, Horwitz RI, and Ioannidis JPA. *JAMA*. 2012; 308(16):1676-1684. Copyright ©2012 American Medical Association. All rights reserved

#### Learning to live with small/tiny effects


Siontis GCM and Ioannidis JPA. Risk factors and interventions with statistically significant tiny effects. *Int J Epidemiol*. 2011; 40(5):1292-1307.

## Large-scale collaboration




Reprinted by permission from Macmillan Publishers Ltd: [*Nat Genet*.] Tobacco and Genetics Consortium. 42(5):441-447, copyright 2012.

## Taking multiplicity into account



#### Nutrient-wide association study



Reprinted from Tzoulaki I, Patel CJ, Okamura T, et al. *Circulation*. 2012; 126(21):2456-2464. Reprinted with permission from Lippincott, Williams, and Wilkins, 2012.

### Validated heatmaps for nutrients




Figure 4. Pearson coefficient correlation heatmap showing all nutrients and potential confounders examined in (A) INTERMAP total population and (B) NHANES total population. Nutrients are clustered according to a hierarchical clustering algorithm in INTERMAP, grouping highly correlated factors closer to one another. For NHANES, the clustering of INTERMAP samples has been used. Correlation coefficients are adjusted for age, sex, and sample (INTERMAP)/cohort (NHANES). INTERMAP indicates International Collaborative Study on Macro-/Micronutrients and Blood Pressure; NHANES, National Health and Nutrition Examination Survey.

Reprinted from Tzoulaki I, Patel CJ, Okamura T, et al. *Circulation*. 2012; 126(21):2456-2464. Reprinted with permission from Lippincott, Williams, and Wilkins, 2012.

# Improving research reporting standards: STROBE-ME, 2011

Gallo V, Egger M, McCormack V, et al. STrengthening the Reporting of OBservational studies in Epidemiology – Molecular Epidemiology (STROBE-ME): An Extension of the STROBE Statement. *PLoS Med*. 2011; 8(10).

# Improving research reporting standards: GRIPS, 2011

Janssens AC, Ioannidis JPA, van Duijn CM, et al. Strengthening the reporting of Genetic Risk Prediction Studies: the GRIPS statement. *PLoS Med.* 2011; 8(3).

## Registration

Ioannidis JPA. The Importance of Potential Studies That Have Not Existed and Registration of Observational Data Sets. *JAMA*. 2012; 308(6): 575-576.

## Levels of registration

- Level 0: no registration
- Level 1: registration of dataset
- Level 2: registration of protocol
- Level 3: registration of analysis plan
- Level 4: registration of analysis plan and raw data
- Level 5: open live streaming

Alsheikh-Ali AA, Qureshi W, Al-Mallah MH, et al. Public Availability of Published Research Data in High-Impact Journals. *PLoS One*. 2011; 6(9).



## Repeatability

Ioannidis JPA, Allison DB, Ball CA, et al. Repeatability of published microarray gene expression analyses. *Nat Genet*. 2009; 41(2):149-155.





Figure 1 Summary of the efforts to replicate the published analyses.

Reprinted by permission from Macmillan Publishers Ltd: [*Nat Genet*.] Ioannidis JPA, Allison DB, Ball CA, et al. 41(2):149-155, copyright 2009.

Ioannidis JPA and Khoury MJ. Improving Validation Practices in "Omics" Research. *Science*. 2011; 334(6060):1230-1232.



#### **Table 4.** Suggestions for the future of knowledge integration

#### Knowledge management

Methods for mining published and unpublished data Registration of observational datasets and, when

appropriate, protocols

Availability of raw data and analysis codes

Facilitation of repeatability and reproducibility checks, replication culture

Consideration of live stream information

#### Knowledge synthesis

Facilitation of consortia with prospective measurements

Optimization of multiconsortial space, competition, and communication

Prospective study networks

#### Knowledge translation

Anticipatory rather than post hoc brokering